ValuEngine downgraded shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) from a hold rating to a sell rating in a research note published on Tuesday morning.
Several other research analysts also recently issued reports on TBPH. Cantor Fitzgerald set a $55.00 price objective on shares of Theravance Biopharma and gave the stock a buy rating in a report on Wednesday, July 19th. BidaskClub cut shares of Theravance Biopharma from a hold rating to a sell rating in a research note on Thursday, July 27th. Needham & Company LLC reissued a buy rating on shares of Theravance Biopharma in a research note on Wednesday, August 2nd. Evercore ISI began coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They issued an outperform rating and a $45.00 target price on the stock. Finally, Zacks Investment Research raised shares of Theravance Biopharma from a sell rating to a hold rating in a research note on Tuesday, September 5th. Four research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Theravance Biopharma currently has a consensus rating of Hold and an average target price of $41.86.
Theravance Biopharma (NASDAQ TBPH) traded up $1.76 during trading hours on Tuesday, hitting $28.88. 157,800 shares of the stock traded hands, compared to its average volume of 238,264. Theravance Biopharma has a one year low of $23.15 and a one year high of $43.44. The company has a current ratio of 7.53, a quick ratio of 7.21 and a debt-to-equity ratio of 1.21.
TRADEMARK VIOLATION WARNING: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://stocknewstimes.com/2017/11/17/theravance-biopharma-inc-tbph-cut-to-sell-at-valuengine.html.
In other news, SVP Frank Pasqualone acquired 4,000 shares of the firm’s stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of $26.34 per share, with a total value of $105,360.00. Following the completion of the purchase, the senior vice president now owns 213,180 shares of the company’s stock, valued at $5,615,161.20. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Bradford J. Shafer sold 14,670 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the sale, the executive vice president now directly owns 134,327 shares in the company, valued at $4,133,241.79. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.
A number of institutional investors have recently modified their holdings of TBPH. QS Investors LLC bought a new stake in Theravance Biopharma during the second quarter worth about $100,000. Ameritas Investment Partners Inc. grew its stake in Theravance Biopharma by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 230 shares during the last quarter. Aperio Group LLC bought a new stake in Theravance Biopharma during the second quarter worth about $205,000. BNP Paribas Arbitrage SA grew its stake in Theravance Biopharma by 570.7% during the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 4,383 shares during the last quarter. Finally, Amalgamated Bank bought a new stake in Theravance Biopharma during the second quarter worth about $214,000. 84.55% of the stock is currently owned by hedge funds and other institutional investors.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.